Barclays initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $385 price target The company’s “broad” oncology pipeline positions it for “durable” growth, the analyst tells investors in a research note. The firm sees two “value-inflecting” pivotal data readouts for BeOne – data for its BTK inhibitor in first line mantle cell lymphoma in the second half of 2025 and data in first line gastroesophageal cancer for its PD1 inhibitor, anti-HER2 combination in Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- Optimistic Buy Rating for BeOne Medicines Driven by Promising Sonrotoclax Trial Results and Market Potential
- BeOne Medicines reports ‘positive’ results from Phase 1/2 study of sonrotoclax
- BeOne Medicines announces EC approved Tevimbra to treat NSCLC
- Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
- Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra